Date |
Links |
 |
| 30 Nov 2009 |
Completion of Placing
The Company announces that it has completed a placing, through WH Ireland Limited, to
raise £782,500 from the issue of 195,625,000 new ordinary shares of 0.04p each (“Ordinary
Shares”) at a price of 0.4p per share (the “Placing”). Application has been made for the new
Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on
4 December 2009.
Read more...
|
|
| 01 Oct 2009 |
Trading Update
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to
update the market on its trading performance for the financial year ended 30 June 2009.
Revenues for the year were stronger than anticipated in a previous trading statement issued
on 28 July 2008 and we were able to build on the improvement set out in the Interim
statement issued in February 2009.
Highlights:
- Revenue for year ended 30 June 2009 is expected to exceed the forecast of £440k made in July 2008
- Good progress on Lilly collaboration, with license agreement signed in April 2009
- Achievement of second year milestone on Tempo project
- Looking to leverage Physiomics’ technology for non-pharmaceutical application
Read more...
|
|
| 23 Jun 2009 |
Update on EC funded TEMPO project
– Achievement of Milestone
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to
announce a successful evaluation, by the European Commission, of the results from the
second year of the research program "TEMPO" . Following this successful review, the
European Commission have agreed that the 3 year “TEMPO” project can continue into its
final year as specified in the original grant proposal.
Read more...
|
|
| 02 Apr 2009 |
Physiomics Announces License
Agreement with Eli Lilly
Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to
announce that it has signed a license agreement with Eli Lilly and Company ('Lilly')
(NYSE: LLY), the global pharmaceutical company. Under the terms of the agreement,
Physiomics will license to Lilly a customised version of its “ModelPlayer” for in silico
simulations of unspecified anticancer drugs and Lilly will have the option to purchase
additional licenses.
Physiomics’ “ModelPlayer” is a stand-alone simulation platform used for in-house
model development that can be out-licensed to partners to allow them to perform
their own simulations using Physiomics’ models. It incorporates a range of features
necessary for developing and calibrating models and simulating anticancer drugs.
Read more...
|
|
| 14 Jul 2008 |
Physiomics Technology in continued and expanded
support of Lilly's Oncology Programs
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce
that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the
global pharmaceutical company, to perform two new projects for in silico simulations in the
field of oncology. Financial details of this agreement have not been disclosed. This follows
the successful completion earlier this year of a specific project studying cancer cellular
processes for drugs targeting the cell cycle (the natural process of controlling cell proliferation).
Read more...
|
|
| 13 Feb 2008 |
Physiomics to present on Chronotherapy at the Annual Meeting of American
Association of Cancer Research (“AACR”)
Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that
it will be participating in the 2008 AACR Annual Meeting, taking place in San Diego, on 12-16 April 2008.
Dr Eric Fernandez will present a development update on the Company’s chronotherapy research program,
as part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics) project. The abstract
will be published in the 2008 Proceeding of the AACR and will be presented in the poster session “Cellular
and Molecular Biology 8”, scheduled for 1:00 pm on 13 April.
Read more...
|
|
| 17 Dec 2007 |
MOU with Swansea University (access to Supercomputer “Blue C”)
Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it has signed a
Memorandum of Understanding ('MOU') with the Institute of Life Science of Swansea University,
which will provide mutual benefits. Under the terms of the MOU, Physiomics will have access to the
Supercomputer “Blue C”, one of the most powerful computers in the world dedicated to Life Science
and is the result of a collaboration between the University, the Welsh Assembly Government and computer
giant IBM. This will reinforce Physiomics’ modelling framework and help to address the ever increasing
computing requirements in the field of System Biology.
Read more...
|
|
| 12 Dec 2007 |
Physiomics Collaboration Update – Cancer Cell Death Model Developed
ValiRx, the cancer therapeutics company, today announces that Phase 1 of its collaboration
with Physiomics plc, the European systems biology simulation company, has been completed.
Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology
has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the
Apoptosis Model.
Read more...
|
|
| 17 Sep 2007 |
Physiomics Technology in support of Eli Lilly Oncology Program
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed an
agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to provide in silico
simulations of cancer cellular processes in support of Lilly's cancer drug discovery research.
Read more...
|
|
| 15 Feb 2007 |
Agreement announced between ValiRx plc and Physiomics plc
ValiRx, the cancer therapeutics company, has signed a new agreement with Physiomics to use its
in silico simulations of cellular processes to reduce the development time and costs associated
in identifying new therapeutic compounds for the treatment of cancers.
Read more...
|
|
| 28 Nov 2006 |
Physiomics plc Announces its Participation in the European TEMPO Project
Physiomics plc is pleased to announce that it has been selected to participate in the TEMPO
(Temporal Genomics for Tailored Chemotherapeutics) Project as one of four Industry partners
working closely with four distinguished European academic research groups.
Read more...
|
|
| 25 Oct 2005 |
Major Technical Advance
Physiomics plc has developed a
sophisticated addition to its core cell growth model showing why different
cancer cells respond in different ways to an innovative new class of anti-cancer drugs.
This was presented at the International Conference on Systems Biology meeting in Boston,
USA, 19th-21st October 2005.
Read more...
|
|
| 23 Jun 2005 |
Physiomics and Bayer launch a new Service
Physiomics and Bayer Technology Services GmbH (BTS) have signed an agreement under which BTS
has appointed Physiomics as a distributor of its PK-Sim® pharmacokinetic modelling
products and services for a renewable five-year period.
Read more...
|
|
| 24 Dec 2004 |
UK Patent Registered to Physiomics
Physiomics plc has received formal notification from the UK
Patent Office of registration to it in the UK of European Patent 0 937 286,
which covers its SystemCell™ simulation technology. The corresponding US
Patent 6,446,055 was granted on 3 September 2002 and assigned to Physiomics
on 14 November 2002.
Read more...
|
|
| 23 Nov 2004 |
Physiomics and Cronos Therapeutics to develop GeneICE for cancer treatment
Physiomics plc and Cronos Therapeutics Ltd (now ValiRx plc) have entered into an alliance
whereby Physiomics will use its novel in silico technology to select optimal targets
for the highly-selective GeneICE technology from Cronos Therapeutics. The alliance
will then codevelop the lead GeneICE constructs.
Read more...
|
|
| 14 Sep 2004 |
Bayer Technology Services and Physiomics sign collaboration
Bayer Technology Services, the engineering and applied science spin-off company of Bayer AG, and
Physiomics plc announced today an agreement to cooperate in the field of clinical response prediction.
Read more...
|
|
| Mar 2003 |
SMART Award
Oxford-based Physiomics plc announces it has received a SMART award for work into the feasibility of developing a Rational Therapy Design system.
Read more...
|
|
